人源抗菌肽LL-37的原核表达及活性鉴定

目的:实现大肠杆菌高效可溶表达人源抗菌肽LL-37。方法:LL-37基因克隆至原核载体pET32a,于大肠杆菌BL21(DE3)中诱导表达。运用相关生物信息学软件分析重组蛋白Trx-LL-37的理化性质、亲/疏水性、蛋白质二级结构及其可溶表达概率。实验还考察了不同诱导温度对重组蛋白可溶表达比例的影响。结果:生物信息学分析显示,Trx-LL-37分子量21.5kD,理论等电点6.3,物理性质稳定,二级结构简单,具有可溶表达倾向。重组蛋白最佳诱导温度为17℃,与37℃相比,可溶表达比例由37.2%提高至50.2%,并且总表达量也提高了5%左右。抑菌结果显示纯化产物对多种常见细菌的生长具有抑制作用。结论:可采用融合方式通过原核系统高效可溶表达LL-37,为LL-37的功能研究打下基础。     

新型断裂内含肽介导的可控性C端断裂

内含肽介导的蛋白质断裂被广泛地应用于蛋白质纯化、连接和环化. 但目前的方法都是用传统的连续的内含肽来介导蛋白质断裂反应,因而往往存在自发性断裂、产率低等问题. 本实验选择3个S1型新型断裂内含肽Ter ThyX、Ssp GryB和Rma DnaB来实现蛋白质断裂反应的可控性. 在可控性C端断裂反应中,S1型断裂内含肽的C端片段（IC ）与硫氧还蛋白（T）融合作为前体蛋白,加入化学合成的Ssp DnaB S1型断裂内含肽 的N端小肽与二硫苏糖醇（DTT）共同诱导C端断裂反应.结果表明,该小肽可以诱导这 3个不同的S1型断裂内含肽的前体蛋白发生C端断裂反应. 该方法为利用内含肽C端断 裂介导的蛋白质纯化提供了更多的选择,并为内含肽的结构与功能的关系研究提供-有用的线索.     

内含肽在构建亲和纯化系统中的应用

内含肽是前体未成熟蛋白中的一段具有自我剪接功能的多肽链,在蛋白质纯化、蛋白质连接、环肽制备、蛋白标记以及生物传感器等方面广泛应用。本文综述了内含肽应用于蛋白质亲和纯化的发展历程,分别对层析型和非层析型内含肽纯化体系进行了分析和讨论,并总结了对控制内含肽断裂反应所进行的研究,为进一步改善内含肽介导蛋白质纯化提供依据和线索。     

人LL-37与干扰素α2a密码子的优化及其在毕赤酵母中的融合表达

通过密码子优化,在毕赤酵母中高效表达人LL-37与IFN-α2a融合蛋白。先按P.pastoris密码子偏好性对LL-37与IFN-α2a的原始密码子进行了改造,并在二者之间加上Gly Gly Gly Gly Ser的柔性连接接头,人工合成设计的新序列,最后通过p PIC9K载体将其整合入P.pastoris GS115的基因组,构建出重组菌株GS115LI。利用遗传霉素浓度梯度筛选出两株高拷贝的GS115LI1和GS115LI2菌株。对这两株菌经发酵诱导后的发酵液进行SDS-PAGE检测、抗病毒活性检测和抗菌活性检测,证明重组株既能够成功表达出LL-37与IFN-α2a的融合蛋白,而且该融合蛋白成功保留了抗菌肽与干扰素的功能活性。诱导发酵后,融合蛋白的产量可达到819.1 mg/L,经盐析、疏水层析和离子交换层析分离,可得到纯度达97%的融合蛋白产物,回收率可达到46.2%,纯化后产品的效价可达2.6×108 IU/mg。经过密码子优化后,成功实现在毕赤酵母中高效表达出既有LL-37抗菌活性又具有干扰素α2a活性的融合蛋白。     

胸腺肽α1-Spl DnaX内含肽融合蛋白的切割动力学研究

目的:研究胸腺肽α1(Tα1)与Spl DnaX内含肽融合蛋白AS的体外切割动力学。方法:构建Tα1和SplDnaX内含肽的融合表达载体pET-AS,转化大肠杆菌BL21(DE3),经乳糖诱导获得可溶性表达的融合蛋白AS,用镍亲和层析纯化该蛋白;综合评价温度、β-巯基乙醇(β-ME)浓度和诱导切割时间对Spl DnaX内含肽介导融合蛋白AS自切割释放Tα1的影响。结果:在大肠杆菌中诱导表达了融合蛋白AS,经镍柱纯化获得该蛋白;随着温度升高和β-ME浓度增加,诱导切割时间延长,Spl DnaX内含肽介导的切割率逐渐增大;最终采用300 mmol/Lβ-ME切割24 h,融合蛋白的硫解切割率大于90%。结论:通过对Spl DnaX内含肽的诱导切割条件进行摸索,确定了最适宜的切割条件,为利用该方法制备Tα1和其他小分子多肽提供了技术基础。     

人源抗菌肽LL-37

LL-37是迄今在人体中发现的抗菌肽cathelicidin家族中的唯一成员,也是人体内唯一的双亲性α螺旋结构的抗菌肽. LL-37在人体的血液细胞和上皮细胞中广泛分布,具有广谱抗菌作用.抗菌活性依赖其螺旋构象的形成,通过“地毯样”机制杀灭细菌. LL-37有中和内毒素的作用,能与LPS和CD14结合,中和LPS的生物活性,还能利用formyl peptide receptor-like 1 (FPRL1) 作为受体介导趋化作用,招募免疫细胞到感染部位,清除病原物. 很多感染性疾病都与LL-37低表达或功能失活有关. LL-37是一种多功能的抗菌肽,有开发成为具有抗菌和增强免疫力双重作用药物的潜力.     

基于PHA颗粒-PhaP标签和内含肽元件的极端嗜盐古菌蛋白的表达纯化系统

【目的】建立一个基于PHA颗粒-PhaP标签的简便实用的极端嗜盐古菌蛋白表达纯化系统,并探讨嗜盐古菌内含肽在该系统优化中的应用。【方法】以嗜盐古菌-大肠杆菌穿梭载体pWL502为基本骨架,构建带有嗜盐古菌强启动子和PhaP融合标签的表达载体;在地中海富盐菌phaP缺陷株(ΔphaP)中融合表达目的基因,通过蔗糖密度梯度离心分离纯化结合于PHA颗粒上的PhaP融合蛋白;在phaP基因与多克隆位点之间引入特定的嗜盐古菌内含肽元件,尝试通过定点突变改变该内含肽的剪切活性。【结果】成功构建了以PhaP作为N端融合标签的表达载体pPM以及作为C端融合标签的载体pIP;在phaP基因簇强启动子控制下,二者均实现了目标蛋白的高效表达;通过PHA颗粒介导的蛋白分离纯化策略,实现了以PhaP为融合标签的目标蛋白的分离纯化;发现内含肽序列Hbt21在地中海富盐菌中保持了高效的剪接活性,通过定点突变其C端末位氨基酸天冬酰胺(N182)及邻位的丝氨酸(S183)失活了该内含肽的C端剪接活性。【结论】首次建立了一个基于PHA颗粒-PhaP标签的简便节约的极端嗜盐古菌蛋白表达纯化系统,并确定了嗜盐古菌型内含肽C端剪接的活性位点,为该内含肽将来应用于PhaP融合蛋白的标签去除奠定了基础。     

人源抗菌肽LL-37在毕赤酵母中的高效表达及其活性检测

根据GenBank CAA86115中的LL-37氨基酸序列,选择毕赤酵母偏好密码子,采用SOE 方法合成了人源抗菌肽LL-37基因.所合成的LL-37基因全长为141 bp,并在其N端引入kex2裂解位点,以保证表达抗茵肽具有天然N端.基因克隆入pPICZα-A质粒,构建分泌型重组酵母表达载体pPICZα-A-LL-37.pPICZα-A-LL-37经Sac Ⅰ酶切线性化后电转化导入毕赤酵母菌株X-33.PCR鉴定为阳性的酵母转化子经甲醇诱导分泌LL-37于发酵上清液,其表达量为206mg/L.表达产物LL-37耐热性强,在100℃条件下40 min内抗茵活性不变,煮沸3 h以上仍具有活性.琼脂糖孔穴扩散法检测显示LL-37对多种革兰氏阴性茵和阳性菌均具有很好的抑制活性,其对金黄色葡萄球菌Cowan I (Staphylococcus aureus)、致病性大肠杆菌K99(Enteropathogenic E.coli)和鸡白痢沙门氏菌(Salmonella pullorum)的最小抑菌浓度(Minimal Inhibitory Concentration,MIC)分别为1.56 μg/mL、3.12 μg/mL和1.56 μg/mL.     

人源抗菌肽LL-37在毕赤酵母中的高效表达及其活性检测

根据GenBank CAA86115中的LL-37氨基酸序列, 选择毕赤酵母偏好密码子, 采用SOE方法合成了人源抗菌肽LL-37基因。所合成的LL-37基因全长为141 bp, 并在其N端引入kex2裂解位点, 以保证表达抗菌肽具有天然N端。基因克隆入pPICZa-A质粒, 构建分泌型重组酵母表达载体pPICZa-A-LL-37。pPICZa-A-LL-37经SacⅠ酶切线性化后电转化导入毕赤酵母菌株X-33。PCR鉴定为阳性的酵母转化子经甲醇诱导分泌LL-37于发酵上清液, 其表达量为206 mg/L。表达产物LL-37耐热性强, 在100℃条件下40 min内抗菌活性不变, 煮沸3 h以上仍具有活性。琼脂糖孔穴扩散法检测显示LL-37对多种革兰氏阴性菌和阳性菌均具有很好的抑制活性, 其对金黄色葡萄球菌 CowanⅠ(Staphylococcus aureus)、致病性大肠杆菌K99(Enteropathogenic E.coli)和鸡白痢沙门氏菌(Salmonella pullorum)的最小抑菌浓度(Minimal Inhibitory Concentration, MIC)分别为1.56 mg/mL、3.12 mg/mL和1.56 mg/mL。     

抗菌肽LL-37及其衍生物对肝癌细胞HepG-2增殖和凋亡的影响效果比较

目的:比较抗菌肽LL-37及其衍生物对肝癌细胞HepG-2增殖和凋亡的影响。方法:以肝癌细胞HepG-2为靶细胞,采用不同浓度抗菌肽LL-37及其衍生物处理后,通过四甲基偶氮噻唑蓝(MTT)比色法检测细胞的增殖情况,流式细胞术Annexin V/PI双染色测定细胞的凋亡情况。结果:随着抗菌肽LL-37及其衍生物作用浓度的增加和作用时间的延长,其对肝癌细胞增殖的抑制作用逐渐增强,二者的浓度都达到300μg/m L时作用72 h,对肝癌细胞增殖的抑制作用最大(P0.01),且抗菌肽LL-37衍生物对肝癌细胞增殖的抑制率高于抗菌肽LL-37。流式检测结果显示:抗菌肽LL-37衍生物诱导的细胞凋亡率高于抗菌肽LL-37。结论:抗菌肽LL-37衍生物在抗肝癌细胞增殖和促进其凋亡方面的作用优于抗菌肽LL-37。     

Expression and purification of a recombinant LL-37 from Escherichia coli

Human cathelicidin-derived LL-37 is a 37-residue cationic, amphipathic alpha-helical peptide. It is an active component of mammalian innate immunity. LL-37 has several biological functions including a broad spectrum of antimicrobial activities and LPS-neutralizing activity. In order to determine the high-resolution three-dimensional structure of LL-37 using NMR spectroscopy, it is important to obtain the peptide with isotopic labels such as (15)N, (13)C and/or (2)H. Since it is less expensive to obtain such a peptide biologically, in this study, we report for the first time a method to express in E. coli and purify LL-37 using Glutathione S-transferase (GST) fusion system. LL-37 gene was inserted into vector pGEX-4T3 and expressed as a GST-LL-37 fusion protein in BL21(DE3) strain. The recombinant GST-LL-37 protein was purified with a yield of 8 mg/l by affinity chromatography and analyzed its biochemical and spectroscopic properties. Factor Xa was used to cleave a 4.5-kDa LL-37 from the GST-LL-37 fusion protein and the peptide was purified using a reverse-phase HPLC on a Vydac C(18) column with a final yield of 0.3 mg/l. The protein purified using reverse-phase HPLC was confirmed to be LL-37 by the analyses of Western blot and MALDI-TOF-Mass spectrometry. E. coli cells harboring the expression vector pGEX-4T3-LL-37 were grown in the presence of the (15)N-labeled M9 minimal medium and culture conditions were optimized to obtain uniform (15)N enrichment in the constitutively expressed LL-37 peptide. These results suggest that our production method will be useful in obtaining a large quantity of recombinant LL-37 peptide for NMR studies.     

Expression and purification of a recombinant LL-37 from Escherichia coli

Human cathelicidin-derived LL-37 is a 37-residue cationic, amphipathic α-helical peptide. It is an active component of mammalian innate immunity. LL-37 has several biological functions including a broad spectrum of antimicrobial activities and LPS-neutralizing activity. In order to determine the high-resolution three-dimensional structure of LL-37 using NMR spectroscopy, it is important to obtain the peptide with isotopic labels such as ¹⁵N, ¹³C and/or ²H. Since it is less expensive to obtain such a peptide biologically, in this study, we report for the first time a method to express in E. coli and purify LL-37 using Glutathione S-transferase (GST) fusion system. LL-37 gene was inserted into vector pGEX-4T3 and expressed as a GST-LL-37 fusion protein in BL21(DE3) strain. The recombinant GST-LL-37 protein was purified with a yield of 8 mg/l by affinity chromatography and analyzed its biochemical and spectroscopic properties. Factor Xa was used to cleave a 4.5-kDa LL-37 from the GST-LL-37 fusion protein and the peptide was purified using a reverse-phase HPLC on a Vydac C₁₈ column with a final yield of 0.3 mg/l. The protein purified using reverse-phase HPLC was confirmed to be LL-37 by the analyses of Western blot and MALDI-TOF-Mass spectrometry. E. coli cells harboring the expression vector pGEX-4T3-LL-37 were grown in the presence of the ¹⁵N-labeled M9 minimal medium and culture conditions were optimized to obtain uniform ¹⁵N enrichment in the constitutively expressed LL-37 peptide. These results suggest that our production method will be useful in obtaining a large quantity of recombinant LL-37 peptide for NMR studies.     

A novel method for purifying recombinant human host defense cathelicidin LL-37 by utilizing its inherent property of aggregation

The importance of human LL-37 in host defense and innate immunity is well appreciated as reflected by an exponential increase of relevant literature in Pub-Med. Although several articles reported the expression and purification of this cathelicidin, some protocols suffered from low efficiency in enzyme cleavage of fusion proteins due to aggregation and poor separation of recombinant LL-37 from the carrier protein on reverse-phase HPLC. We present a new method for purifying LL-37 that avoids both problems. In this method, the fusion protein (a tetramer) purified by metal affinity chromatography was readily cleaved at a thrombin site 30-residue upstream of the LL-37 sequence. The released LL-37-containing fragment formed a large soluble aggregate (approximately 95 kDa) at pH approximately 7, allowing a rapid and clean separation from the carrier thioredoxin (approximately 14 kDa) by size-exclusion chromatography. Recombinant LL-37 was released from the isolated aggregate by chemical cleavage in 50% formic acid at 50 degrees C for 32 h. Due to a dramatic difference in retention time, recombinant LL-37 was well resolved from the S-Tag-containing peptide by RP-HPLC. Compared to previous procedures, the new method involves fewer steps and is highly reproducible. It increases peptide yield by 53%. NMR data support the aggregation of LL-37 into a tetramer with increase of pH as well as the feasibility of structural studies of an isotope-labeled antimicrobial peptide in the lipid micelle of dioctanoyl phosphatidylglycerol (D8PG) for the first time.     

The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses

The role of LL-37, a human cationic antimicrobial peptide, in the immune system is not yet clearly understood. It is a widely expressed peptide that can be up-regulated during an immune response. In this report, we demonstrate that LL-37 is a potent antisepsis agent with the ability to inhibit macrophage stimulation by bacterial components such as LPS, lipoteichoic acid, and noncapped lipoarabinomannan. We also demonstrate that LL-37 protects mice against lethal endotoxemia. In addition to preventing macrophage activation by bacterial components, we hypothesized the LL-37 may also have direct effects on macrophage function. We therefore used gene expression profiling to identify macrophage functions that might be modulated by LL-37. These studies revealed that LL-37 directly up-regulates 29 genes and down-regulated another 20 genes. Among the genes predicted to be up-regulated by LL-37 were those encoding chemokines and chemokine receptors. Consistent with this, LL-37 up-regulated the expression of chemokines in macrophages and the mouse lung (monocyte chemoattractant protein 1), human A549 epithelial cells (IL-8), and whole human blood (monocyte chemoattractant protein 1 and IL-8), without stimulating the proinflammatory cytokine, TNFalpha. LL-37 also up-regulated the chemokine receptors CXCR-4, CCR2, and IL-8RB. These findings indicate that LL-37 may contribute to the immune response by limiting the damage caused by bacterial products and by recruiting immune cells to the site of infection so that they can clear the infection.     

Recombinant expression of human cathelicidin (hCAP18/LL-37) in <Emphasis Type="Italic">Pichia pastoris</Emphasis>

The constitutive expression of human cathelicidin LL-37 antimicrobial peptide was achieved using the methylotrophic yeast, Pichia pastoris. An LL-37 cDNA clone was amplified by PCR using human fetal cDNA library as template. The 111 bp fragment encoding mature LL-37 gene was subcloned into pGAPZ-E, an episomal form of the pGAPZB vector incorporating PARS1. It was then transformed into the P. pastoris X-33 strain for intracellular expression. A small peptide with a molecular mass of about 5 kDa was detected by 17% peptide-PAGE analysis. The recombinant LL-37 peptide was purified from the gel and its amino acid sequence was determined by LC-ESI-MS/MS analysis. The initiating amino acid, methionine, was still attached to the N-terminal region of recombinant LL-37. LL-37 crude extract from P. pastoris showed an antimicrobial activity against Micrococcus luteus as the test strain. The successful expression of human LL-37 indicates that the system may be applicable to the expression of other human defensins without resorting to fusion protein constructions.     

Cloning, expression, isotope labeling, and purification of human antimicrobial peptide LL-37 in Escherichia coli for NMR studies

Antimicrobial peptide LL-37 plays an important role in human body's first line of defense against infection. To better understand the mechanism of action, it is critical to elucidate the three-dimensional structure of LL-37 in complex with bacterial membranes. We present a bacterial expression system that allows the incorporation of (15)N and other isotopes into the polypeptide for nuclear magnetic resonance (NMR) analysis. The DNA sequence encoding full-length LL-37 was chemically synthesized and cloned into the pET-32a(+) vector for protein expression in Escherichia coli strain BL21(DE3). The peptide was expressed directly as a His-tagged fusion protein without the inclusion of its precursor sequence. LL-37 was released from the fusion by formic acid cleavage at the AspPro dipeptide bond and separated from the carrier thioredoxin by affinity chromatography and reverse-phase HPLC. The peptide was identified by polyacrylamide gel electrophoresis and further confirmed by mass spectrometry and NMR spectroscopy. Antibacterial activity assays showed that the recombinant LL-37 purified from the bacterial source is as active as that from chemical synthesis. According to the antimicrobial peptide database (), 111 peptides contain a Met residue, but only 5 contain the AspPro pair, indicating a broader application of formic acid than cyanogen bromide in cleaving fusion proteins. The successful application to the expression of the 66-residue cytoplasmic tail of human MUC1 indicates that the system can be applied to other peptides as well.     

On-resin cleavage of bacterially expressed fusion proteins for purification of active recombinant peptides SK-29, KR-20, LL-29, and LL-23 from human sweat or skin

Post-translational processing of host defense cathelicidin peptide LL-37 in human sweat and skin generates new antimicrobial peptides. To understand structure and mechanism of action of these LL-37 derivatives, this article presents the cloning and expression of SK-29, KR-20, LL-29, and LL-23. We also provide a two-step chromatographic purification protocol of general use. First, resin-bound fusion proteins were directly subject to efficient upstream thrombin cleavage to release peptide-containing fragments. The resin, resin-bound carrier, and residual uncut fusion proteins were subsequently removed by centrifugation. Second, the peptide-containing fragments were digested with formic acid to release the required peptides followed by reverse-phase HPLC purification. We obtained 1.7 mg of recombinant SK-29, 0.7 mg KR-20, 2.1mg LL-29, and 5.4 mg LL-23, each from one liter of rich medium culture. Analytical HPLC, MS, and NMR indicated high quality of all the purified peptides. Antibacterial assays revealed the minimum inhibitory concentrations (MIC) for SK-29, KR-20, LL-29, and LL-23 are 80, 60, 40, and >150 microM, respectively. The poorest toxicity of LL-23 to Escherichia coli K12 correlates with its higher level of bacterial expression, reduced aggregation tendency, and loss of binding to a yet-to-be-characterized molecular target. Thus, on-resin protein cleavage facilitates the evaluation of peptide aggregation ability and may allow the identification of potential new bacterial targets of antimicrobial peptides. On-resin cleavage may be applied to the release of membrane proteins expressed as fusions.     

Intein-mediated protein purification of fusion proteins expressed under high-cell density conditions in E. coli

The intein-mediated purification system has the potential to significantly reduce the recovery costs of industrial recombinant proteins. The ability of inteins to catalyze a controllable peptide bond cleavage reaction can be used to separate a recombinant protein from its affinity tag during affinity purification. Inteins have been combined with a chitin-binding domain to serve as a self-cleaving affinity tag, facilitating highly selective capture of the fusion protein on an inexpensive substrate--chitin (IMPACT) system, New England Biolabs, Beverly, MA). This purification system has been used successfully at a lab scale in low cell density cultures, but has not been examined comprehensively under high-cell density conditions in defined medium. In this study, the intein-mediated purification of three commercially relevant proteins expressed under high-cell density conditions in E. coli was studied. Additionally, losses during the purification process were quantified. The data indicate that the intein fusion proteins expressed under high cell density fermentations were stable in vivo after induction for a significant duration, and the intein fusion proteins could undergo thiol or pH and temperature initiated cleavage reaction in vitro. Thus, the intein-mediated protein purification system potentially could be employed for the production of recombinant proteins at the industrial-scale.     

Expression of bioactive recombinant GSLL-39, a variant of human antimicrobial peptide LL-37, in Escherichia coli

The human cationic antimicrobial peptide hCAP-18/LL-37 is the unique cathelicidin identified in human to date. It has broad spectrum of antimicrobial activities and LPS-neutralizing activity and is involved in angiogenesis. Both purified and synthetic LL-37 or its derivatives were used in the study on LL-37. However, production of LL-37 in Escherichia coli has not been established. In this study, its precursor instead of the mature peptide was adopted for expression to avoid the lethal effect of recombinant LL-37 on host cells. A thrombin recognition site was introduced between the cathelin-like domain and LL-37 domain by overlap PCR to construct fragment encoding modified precursor (mhCAP-18) to facilitate the final release of the recombinant peptide. Then mhCAP-18 was fused in-frame to thioredoxin gene under the control of inducible T7 promoter to construct expression vector pET-mhCAP-18. The soluble form fusion protein was expressed in E. coli and purified by Chelating Sepharose column chromatography. Thrombin digestion of the fusion protein yielded recombinant GSLL-39, which was then purified by cation-exchange chromatography. Recombinant GSLL-39, which has two extra residues on its N-terminus when compared with its native counterpart, showed similar antimicrobial activities against both Gram-negative and Gram-positive bacteria.     

Novel and economical purification of recombinant proteins: intein-mediated protein purification using in vivo polyhydroxybutyrate (PHB) matrix association

This work combines two well-established technologies to generate a breakthrough in protein production and purification. The first is the production of polyhydroxybutyrate (PHB) granules in engineered strains of Escherichia coli. The second is a recently developed group of self-cleaving affinity tags based on protein splicing elements known as inteins. By combining these technologies with a PHB-specific binding protein, a self-contained protein expression and purification system has been developed. In this system, the PHB-binding protein effectively acts as an affinity tag for desired product proteins. The tagged product proteins are expressed in E. coli strains that also produce intracellular PHB granules, where they bind to the granules via the PHB-binding tag. The granules and attached proteins can then be easily recovered following cell lysis by simple mechanical means. Once purified, the product protein is self-cleaved from the granules and released into solution in a substantially purified form. This system has been successfully used at laboratory scale to purify several active test proteins at reasonable yield. By allowing the bacterial cells to effectively produce both the affinity resin and tagged target protein, the cost associated with the purification of recombinant proteins could be greatly reduced. It is expected that this combination of improved economics and simplicity will constitute a significant breakthrough in both large-scale production of purified proteins and enzymes and high-throughput proteomics studies of peptide libraries.